BNP PARIBAS ARBITRAGE/PUT/MODERNA/140/0.01/20.12.24 | Market Closed - Borsa Italiana 04:04:59 2024-07-05 pm EDT | ||
| 0.279 EUR | -0.36% |
|
| Current month | +3.27% | ||
| 1 month | +92.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 0.2845 | +1.61% |
| 24-07-04 | 0.28 | -5.56% |
| 24-07-03 | 0.2965 | +3.67% |
| 24-07-02 | 0.286 | -2.56% |
| 24-07-01 | 0.2935 | +6.53% |
Real-time Borsa Italiana
Last update July 05, 2024 at 04:04 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| P216E9 | |
| ISIN | NLBNPIT216E9 |
| Date issued | 2024-03-26 |
| Strike | 140 $ |
| Maturity | 2024-12-20 (168 Days) |
| Parity | 100 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.409 € |
|---|---|
| Lowest since issue | 0.116 € |
| Spread | 0.003 € |
| Spread % | 1.07% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.3
USD
Average target price
145.9
USD
Spread / Average Target
+23.27%
- Stock Market
- Warrants
- P216E9 Warrant
